Date: 2011-07-12
Type of information: Development agreement
Compound:
Company: Roche NimbleGen (Switzerland) Caliper Life Sciences (USA)
Therapeutic area:
Type agreement: development
marketing
commercialisation
Action mechanism:
Disease:
Details: Roche NimbleGen and Caliper Life Sciences have announced a co-marketing agreement for the development and optimization of automated protocols for the NimbleGen SeqCap EZ Library solution-based capture method for Caliper’s Sciclone NGS Workstation. The collaboration aims to simplify high throughput targeted resequencing workflows by developing automated methods for sequencing library preparation and enrichment of target regions, quantification, and quality control. The automated methods will enable biomedical researchers worldwide to analyze large cohorts to discover and confirm genetic variants that contribute to human disease.
Financial terms: Financial details were not disclosed.
Latest news:
